Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Okadaic acid (also known as 9,10-Deepithio-9,10-didehydroacanthifolicin and halochondrine A) is a naturally occurring polyether toxin produced by marine dinoflagellates and isolated from marine sponges. It is a potent and selective inhibitor of serine/threonine protein phosphatases, specifically targeting protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), with much higher affinity for PP2A. By inhibiting these enzymes, okadaic acid induces hyperphosphorylation of cellular proteins. This mechanism disrupts normal cell signaling pathways regulated by phosphorylation and has been widely used as a research tool to study these processes. Okadaic acid is also recognized as a tumor promoter and one of the primary causes of diarrhetic shellfish poisoning in humans[1][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on okadaic acid.